Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of AMC6156 in People With Sarcopenia
Sponsor: Animuscure Inc.
Summary
This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.
Official title: A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-07-01
Completion Date
2026-06
Last Updated
2025-07-29
Healthy Volunteers
No
Conditions
Interventions
AMC6156 0.1mg
Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.
AMC6156 0.3mg
Oral administration of AMC6156 in tablet form at a dose of 0.3 mg once daily for 12 weeks.
AMC6156 1.0mg
Oral administration of AMC6156 in tablet form at a dose of 1.0 mg once daily for 12 weeks.
Placebo
Oral administration of placebo tablets matching AMC6156 in appearance, once daily for 12 weeks.
Locations (4)
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea
Seoul National University Hospital
Seoul, Seoul, South Korea